Work

A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin

Year: 2015

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-015-0278-7

Authors: Jhanelle E. Gray, Jeffrey R. Infante, Les H. Brail, George R. Simon, Jennifer F. Cooksey, Suzanne F. Jones, Daphne L. Farrington, Adeline Yeo, Kimberley A. Jackson, Kay H. Chow, Maciej J. Zamek-Gliszczynski, Howard A. Burris

Institutions: Moffitt Cancer Center, Sarah Cannon, Tennessee Oncology, Eli Lilly (United States), Infinity Pharmaceuticals (United States), The University of Texas MD Anderson Cancer Center, GlaxoSmithKline (United States)

Language: English

Topic: Wnt/β-catenin signaling in development and cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Eli Lilly and Company

OpenAlex ID: W2095971007

FWCI: 2.193

Cites: 22

Cited by: 75

Related to: 10